EQT Life Sciences leads EUR 93 million oversubscribed Series A round in Pantera, which aims to accelerate global actinium-225 production
· On track for commercial-scale production of actinium-225, which is crucial to a new class of targeted treatments for cancer · Largest Series A in life sciences sector in Belgium to date; led by EQT Life Sciences · Total of EUR 134 million raised including funding secured through EUR 7.2 million equity from IBA and SFPIM, and EUR 33.8 million debt financingEQT Life Sciences is pleased to announce that it has led a EUR 93 million oversubscribed Series A fundraise in PanTera, the Belgian radioisotope producer. With additional equity and debt funding, the total amount raised is EUR 134